SCHEMBL4523968

SCHEMBL4523968

Cc1nc(=O)c(CS(=O)(=O)c2ccccc2)c[nH]1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 2/20 0.43
TDP1 Q9NUW8 2/20 0.42
ALDH1A1 P00352 4/20 0.41
HTT P42858 2/20 0.41
MAPT P10636 2/20 0.41
KMT2A Q03164 2/20 0.41
KDM4E B2RXH2 1/20 0.41
MPI P34949 1/20 0.41
APOBEC3G Q9HC16 1/20 0.41
PSIP1 O75475 1/20 0.41
SMN1; SMN2 Q16637 3/20 0.40
NPC1 O15118 2/20 0.38
RAB9A P51151 2/20 0.38
PIK3CB P42338 1/20 0.37
DAO P14920 1/20 0.37
MEN1 O00255 1/20 0.36
MCOLN3 Q8TDD5 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
PTGDR2 Q9Y5Y4 1/20 0.36
MPO P05164 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4522928 0.73 POLB (0.44) POLBTDP1ALDH1A1HTTMAPT
SCHEMBL10749372 0.69 CYP19A1 (0.58) POLBTDP1ALDH1A1MAPTKMT2A
SCHEMBL2808506 0.69 PSIP1 (0.54) POLBTDP1ALDH1A1HTTMAPT
SCHEMBL31172117 0.69 PSIP1 (0.54) POLBTDP1ALDH1A1HTTMAPT
SCHEMBL11922695 0.67 PSIP1 (0.61) POLBALDH1A1HTTMAPTKMT2A
SCHEMBL10981391 0.65 NR3C1 (0.60) POLBTDP1ALDH1A1MAPTKMT2A
SCHEMBL7750500 0.64 HSD11B1 (0.55) POLBTDP1ALDH1A1HTTMAPT
SCHEMBL10983690 0.63 TDP1 (0.50) POLBTDP1PSIP1SMN1; SMN2NPC1
SCHEMBL4473849 0.63 ATAD2 (0.44) ALDH1A1KMT2ARAB9AMEN1
SCHEMBL22144496 0.63 PSIP1 (0.46) POLBTDP1ALDH1A1HTTMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2124919-A2 METHODS FOR MODULATING BONE FORMATION AND MINERALIZATION PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2009-12-02 EP claimed
US-20080318987-A1 METHODS FOR MODULATING BONE FORMATION AND MINERALIZATION NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2008-12-25 US claimed
WO-2008103314-A2 METHODS FOR MODULATING BONE FORMATION AND MINERALIZATION PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2008-08-28 WO claimed
EP-2124919-A2 METHODS FOR MODULATING BONE FORMATION AND MINERALIZATION PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2009-12-02 EP disclosed
US-20080318987-A1 METHODS FOR MODULATING BONE FORMATION AND MINERALIZATION NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2008-12-25 US disclosed
WO-2008103314-A2 METHODS FOR MODULATING BONE FORMATION AND MINERALIZATION PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2008-08-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080318987-A1 METHODS FOR MODULATING BONE FORMATION AND MINERALIZATION BMP4, BMP2, SOST POLB 2789/4885TDP1 4711/4885ALDH1A1 3934/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.